How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Press’ post set off a firestorm of controversy within the Haskell community, which is small but vocal, and likely felt the ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Toby Walters is a financial writer, investor, and lifelong learner.

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://www.jstor.org/stable/10.3366/j ...

Once peer review is completed and the editor is satisfied that any concerns raised by the reviewers have been suitably addressed, the paper is accepted ‘in principle’ (AIP). The editor will send ...